TxCell First-Half 2017 Financial Results And Strategy Update
VALBONNE, France--(BUSINESS WIRE)--Regulatory News:
TxCell SA (Paris:TXCL) (FR0010127662 – TXCL), a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, today announces its consolidated financial results for the first half of 2017 and provides an update on its strategy and outlook.
The TxCell Half Year Financial Report as of June 30, 2017 is available on the company’s website www.txcell.com in the Investors / Documentation / AMF regulated information section.
TxCell SA (Paris:TXCL) (FR0010127662 – TXCL), a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, today announces its consolidated financial results for the first half of 2017 and provides an update on its strategy and outlook.
The TxCell Half Year Financial Report as of June 30, 2017 is available on the company’s website www.txcell.com in the Investors / Documentation / AMF regulated information section.